A new study by UMD researchers found that saltier waterways are creating 'chemical cocktails' that release toxic metals and pollutants from streambeds. These cocktails can have devastating effects on drinking water supplies and ecosystems, similar to the 2014 Flint water crisis.
A recent study found that around 72% of women at higher risk of breast cancer are worried about the long-term effects of tamoxifen, while 57% believe it will give them unpleasant side-effects. Despite its proven ability to prevent breast cancer, fewer than 15% of women with discussed preventive therapy are taking tamoxifen.
Researchers discovered that babies with a diverse range of nasal bacteria tend to recover faster from their first respiratory virus. Conversely, those dominated by certain bacterial families are more likely to experience prolonged symptoms.
People with epilepsy living in high-crime Chicago neighborhoods have three times as many seizures as those in low-crime areas, a new study finds. The researchers used data from 63 participants and found that those in high-crime neighborhoods experienced an average of seven seizures over 90 days.
Researchers have discovered that certain naturally occurring yeast strains can produce beneficial acids, improving wine taste and quality. The study focused on Lachancea thermotolerans yeast, which can be used in conjunction with traditional wine yeasts to enhance the flavor profile.
Researchers at Dana-Farber Cancer Institute present positive results from clinical trials of CAR T-cell therapy and immunotherapy for patients with leukemia and lymphoma. The studies show that Yescarta provides durable benefit to lymphoma patients, while pembrolizumab achieves long-lasting responses in patients with an aggressive form ...
A follow-up analysis of axi-cel-treated patients with diffuse large B-cell lymphoma (DLBCL) reported that 51% were still alive two years post-treatment. The study found that 83% achieved a reduction in cancer activity, and 39% had ongoing responses. CAR-T cell persistence and B-cell recovery were also observed in most patients.
Dr. Nazha presents results of a personalized prediction model that surpassed current prediction models for Myelodysplastic Syndromes (MDS), predicting patient mortality and transformation risk with high accuracy.
The study found nearly 40% of large B cell lymphoma patients remained in remission beyond 2 years after receiving Yescarta treatment. Patients with refractory disease showed durable responses, giving hope for a cure.